BRAF and ameloblastoma: The results of DNA sequencing performed in randomly selected 40 <i>BRAF</i> V600E-positive and 20 <i>BRAF</i> V600E-negative ameloblastoma tissues were in accordance with the immunohistochemical findings.<h4>Conclusion</h4>As a result of a notable prevalence of <i>BRAF</i> V600E in Thai individuals diagnosed with ameloblastoma, they may benefit from the utilization of adjunctive anti-BRAF targeted therapy for treatment.